REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
-
SciScore for 10.1101/2021.05.19.21257469: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The local institutional review board or ethics committee at each study center oversaw trial conduct and documentation.
Consent: All patients provided written informed consent before participating in the trial.Sex as a biological variable The phase 3 portion comprised 3 cohorts: Cohort 1 (≥18 years), Cohort 2 (<18 years), and Cohort 3 (pregnant at randomization). Randomization TRIAL DESIGN: This was an adaptive, multicenter, randomized, double-blind, placebo-controlled, phase 1/2/3 master protocol in Covid-19 outpatients (NCT04425629). Blinding The investigators, site personnel, and Regeneron employees who were involved in collecting and analyzing data were unaware of the treatment-group … SciScore for 10.1101/2021.05.19.21257469: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The local institutional review board or ethics committee at each study center oversaw trial conduct and documentation.
Consent: All patients provided written informed consent before participating in the trial.Sex as a biological variable The phase 3 portion comprised 3 cohorts: Cohort 1 (≥18 years), Cohort 2 (<18 years), and Cohort 3 (pregnant at randomization). Randomization TRIAL DESIGN: This was an adaptive, multicenter, randomized, double-blind, placebo-controlled, phase 1/2/3 master protocol in Covid-19 outpatients (NCT04425629). Blinding The investigators, site personnel, and Regeneron employees who were involved in collecting and analyzing data were unaware of the treatment-group assignments. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources All patients were assessed at baseline for anti-SARS-CoV-2 antibodies – anti-spike [S1] IgA, anti-spike [S1] IgG, and anti-nucleocapsid IgG – and grouped for analyses as serum antibody–negative (if all available test results were negative), serum antibody– positive (if any available test result was positive), or other (inconclusive/unknown results). anti-SARS-CoV-2suggested: Noneanti-spike [ S1suggested: Noneanti-spike [ S1 ] IgGsuggested: Noneanti-nucleocapsid IgGsuggested: NoneSoftware and Algorithms Sentences Resources Statistical analyses were performed with SAS software, v9.4 SASsuggested: (SASqPCR, RRID:SCR_003056)4 (SAS Institute). SAS Institutesuggested: (Statistical Analysis System, RRID:SCR_008567)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04425629 Recruiting Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-Co… NCT04426695 Active, not recruiting Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-Co… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-